Keywords:
kanamycin sulfate, kanamycin sulfate’s R&D Progress, Mechanism of Action for kanamycin sulfate, drug target for kanamycin sulfate.
Description:
This article summarized the latest R&D progress of kanamycin sulfate, the Mechanism of Action for kanamycin sulfate, and the drug target R&D trends for kanamycin sulfate.
Text:
kanamycin sulfate‘s R&D Progress
Kanamycin Sulfate is a small molecule drug that primarily targets the 30S subunit. It is used in the treatment of infectious diseases and respiratory diseases, specifically for pulmonary tuberculosis and bacterial infections. The drug has been approved for use i global markets.
Kanamycin Sulfate was approved in China in January 1955, making it one of the earliest drugs to receive approval in the country. It has since gained recognition and approval globally, indicating its effectiveness and safety in treating the specified therapeutic areas.As a small molecule drug, Kanamycin Sulfate works by targeting the 30S subunit, which is a component of bacterial ribosomes. By inhibiting protein synthesis in bacteria, it effectively combats bacterial infections and helps in the treatment of pulmonary tuberculosis. This mechanism of action makes it a valuable tool in the fight against infectious diseases.
The highest R&D phase of this drug is approved. Its long history of use since 1955 further demonstrates its reliability and effectiveness. Kanamycin Sulfate has proven to be a valuable asset in the treatment of infectious diseases, particularly in cases of bacterial infections and pulmonary tuberculosis.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for kanamycin sulfate: 30S subunit
30S subunit inhibitors are a type of drugs that target the 30S subunit of the bacterial ribosome. The bacterial ribosome is responsible for protein synthesis, and it consists of two subunits, the 30S subunit and the 50S subunit. The 30S subunit inhibitors specifically bind to the 30S subunit, interfering with the ribosome’s ability to read the genetic code and synthesize proteins. By inhibiting protein synthesis, these drugs can effectively inhibit bacterial growth and replication. This class of drugs is commonly used in the treatment of bacterial infections and can be effective against a wide range of bacterial species. Examples of 30S subunit inhibitors include tetracyclines and aminoglycosides.
Drug Target R&D Trends for kanamycin sulfate
The 30S subunit is a crucial component of the ribosome, which is responsible for protein synthesis in the human body. It plays a vital role in the initiation and elongation phases of translation, where genetic information from mRNA is decoded into a specific sequence of amino acids. The 30S subunit binds to the mRNA and helps in the selection of the correct transfer RNA (tRNA) molecule carrying the corresponding amino acid. It also facilitates the formation of peptide bonds between the amino acids, leading to the synthesis of proteins essential for various biological processes. Understanding the functioning of the 30S subunit is crucial for developing drugs that target bacterial ribosomes, as they differ from human ribosomes and can be selectively inhibited to treat infections.
According to Patsnap Synapse, as of 5 Sep 2023, there are a total of 109 30S subunit drugs worldwide, from 176 organizations, covering 181 indications, and conducting 1552 clinical trials.
The analysis of the target 30S subunit reveals a competitive landscape with multiple companies focusing on research and development. Pfizer Inc. has the highest stage of development with 6 approved drugs. Bacterial infections are the most targeted indication, with a significant number of approved drugs. Small molecule drugs are progressing rapidly, indicating intense competition in this area. China is leading in terms of the number of approved drugs, followed by the United States and Japan. The future development of the target 30S subunit is promising, with ongoing research and development efforts focused on addressing various indications and drug types.Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In conclusion, Kanamycin Sulfate is a small molecule drug that targets the 30S subunit and is primarily used in the treatment of infectious diseases and respiratory diseases. It has been approved for use in globa markets since its first approval in China in 1955. With its proven efficacy and safety, Kanamycin Sulfate continues to play a crucial role in combating bacterial infections and treating pulmonary tuberculosis.
